---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291434465.md"
description: "iBio shares are trading higher after the company announced that a single dose of its IBIO-610 treatment lowered levels of metabolism regulator protein Activin E in primates for up to 8 weeks."
datetime: "2026-07-01T14:38:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291434465.md)
  - [en](https://longbridge.com/en/news/291434465.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291434465.md)
generator: "portal-rs"
---

# 

iBio shares are trading higher after the company announced that a single dose of its IBIO-610 treatment lowered levels of metabolism regulator protein Activin E in primates for up to 8 weeks.

### Related Stocks

- [IBIO.US](https://longbridge.com/en/quote/IBIO.US.md)

## Related News & Research

- [iBio announces annual shareholder meeting](https://longbridge.com/en/news/298071487.md)
- [iBio FY26 net loss widens to $33.04 million; revenue drops to $100,000](https://longbridge.com/en/news/297313027.md)
- [06:56 ETHow travelers can support wild animals rather than exploit them](https://longbridge.com/en/news/297901620.md)
- [iBio advances IBIO-600 into Phase 1 multiple-ascending-dose trial stage after completing single-ascending-dose dosing](https://longbridge.com/en/news/297325770.md)
- [iBio CEO joins Wells Fargo Annual Healthcare Conference fireside chat](https://longbridge.com/en/news/297695352.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**